Characterization of transendothelial migratory lymphokine-activated killer cells

Japanese Journal of Cancer Research

Volumn 87, Issue 4, 1996, Pages 395-400

  Nakano, Koji ^a   Eura, Masao ^a   Chikamatsu, Kazuaki ^a   Masuyama, Keisuke ^a   Ishikawa, Takeru ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Adhesion molecules; HUVEC; Killing activity; LAK

Indexed keywords

CD2 ANTIGEN;

ARTICLE; CANCER THERAPY; CELL MIGRATION; CONTROLLED STUDY; DAUDI CELL; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; MONOLAYER CULTURE; NORMAL HUMAN; PRIORITY JOURNAL; UMBILICAL VEIN;

EID: 0030032704     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1996.tb00235.x     Document Type: Article

References (27)

1. Rosenberg, S. A., Lotze, M. T. and Muul, L. M. Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med., 313, 1485-1492 (1985).
2. Shu, S., Chou, T. and Rosenberg, S. A. In vitro sensitization and expansion with viable tumor cells and interleukin-2 in the generation of specific therapeutic effector cells. J. Immunol., 136, 3891-3898 (1986).
3. Ariga, A., Yamauchi, K., Takasaki, K., Furukawa, T. and Hanyu, F. Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. Int. J. Cancer, 49, 19-24 (1991).
4. Topalian, S. A., Solomon, D., Avis, F. P., Chang, A. E., Freerksen, D. C., Linehan, W. M., Lotze, M. T., Lobertson, C. N., Seipp, C. A., Simon, P., Simpson, C. G. and Rosenberg, S. A. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol., 6, 839-853 (1988).
5. 111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Cancer, 73, 1731-1737 (1993).
6. Keilholz, U., Schlag, P., Tilgen, W., Brado, B., Galm, F., Gorich, J., Kauffmann, G. W., Moller, P., Schneider, S. and Hunstein, W. Regional administration of lymphokine-activated killer cells can be superior to intravenous application. Cancer, 69, 2172-2175 (1992).
7. Morita, T., Yonese, Y. and Minato, N. In vivo distribution of recombinant interleukin-2-activated autologous lymphocytes administered by intraarterial infusion in patients with renal cell carcinoma. J. Natl. Cancer Inst., 78, 441-447 (1987).
8. Lotze, M. T., Line, B. R., Mathisen, D. J. and Rosenberg, S. A. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J. Immunol., 125, 1487-1493 (1980).
9. Felgar, R. E. and Hiserodt, J. C. In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats. Cell. Immunol., 129, 288-298 (1990).
10. Ishikawa, T., Ikawa, T., Eura, M., Fukiage, T. and Masuyama, K. Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumor cells and recombinant interleukin-2. Acta Otolaryngol., 107, 346-351 (1989).
11. Drake, W. T. and Issekuts, A. C. Transforming growth factor-β1 enhances polymorphonuclear leucocyte accumulation in dermal inflammation and transendothelial migration by a priming action. Immunology, 78, 197-204 (1993).
12. William, A. M. and Weigl, S. A. Monocyte-selective transendothelial migration: dissection of the binding and transmigration phases by an in vitro assay. J. Exp. Med., 176, 819-828 (1992).
13. Bird, N., Spragg, J. H., Ager, A. and Matthews, N. Studies of lymphocyte transendothelial migration: analysis of migrated cell phenotypes with regard to CD31 (PECAM-1), CD45RA and CD45RO. Immunology, 80, 553-560 (1993).
14. Ebisawa, M., Yamada, T., Bickel, C., Klunk, D. and Schleimer, R. P. Eosinophil transendothelial migration induced by cytokines. J. Immunol., 153, 2153-2159 (1994).
15. Kitayama, J., Juji, T., Atomi, Y., Kuroda, A., Muto, T., Kobayashi, M., Mitsui, Y. and Minami, M. Transendothelial migration activity of lymphokine-activated killer (LAK) cells. J. Immunol., 151, 1663-1672 (1993).
16. Delens, N., Torreele, E., Savelkool, H., Baetselier, P. D. and Bouwens, L. Tumor-derived transforming growth factor-β1 and interleukin-6 are chemotactic for lymphokine-activated killer cells. Int. J. Cancer, 57, 696-700 (1994).
17. Jaffe, E. A., Nachman, R., Becker, C. G. and Minik, C. R. Culture of human endothelial cells derived from umbilical veins. J. Clin. Invest., 52, 2745-2756 (1973).
18. Oppenheimer-Marks, N., Davis, L. S. and Lipsky, P. E. Human T lymphocyte adhesion to endothelial cells and transendothelial migration. J. Immunol., 145, 140-148 (1990).
19. Kavanaugh, A. F., Lightfoot, E., Lipsky, P. E. and Oppenheimer-Marks, N. Role of CD11/CD18 in adhesion and transendothelial migration of T cells. J. Immunol., 146, 4149-4156 (1991).
20. Allavena, P., Paganin, C., Martin-Padura, I., Peri, G., Gabori, M., Dejana, E., Marchisio, P. C. and Mantovani, A. Molecules and structures involved in the adhesion of natural killer cells to vascular endothelium. J. Exp. Med., 173, 439-448 (1991).
21. Shimizu, Y., Van Seventer, G. A., Morgan, K. J. and Shaw, S. Roles of adhesion molecules in T-cell recognition: fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-5, VLA-6) in expression, binding, and costimulation. Immunol. Rev., 114, 109-143 (1990).
22. Schmidt, R. E., Caulfield, J. P., Michon, J., Hein, A., Kamada, M. M., Macdemott, R. P., Stevens, R. L. and Ritz, J. T11/CD2 activation of cloned human natural killer cells results in increased conjugate formation and exocytosis of cytolytic granules. J. Immunol., 140, 991-1002 (1988).
23. Patrroyo, M., Prieto, J., Rincon, J., Timonon, T., Lundberg, C., Lindbom, L., Asjo, B. and Gahmberg, C. G. Leukocyte-cell adhesion: a molecular process fundamental in leukocyte physiology. Immunol. Rev., 114, 67-108 (1990).
24. Bolhuis, R. L. H., Roozemond, R. C. and Van De Griend, R. J. Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor. J. Immunol., 136, 3939-3944 (1986).
25. Vennegoor, C. J. G. M., Kemenade, E. W., Huijbens, R. J. F., Sanches-Madrid, F., Melief, C. J. M. and Figdor, C. G. Role of LFA-1 and VLA-4 in the adhesion of cloned normal and LFA-1 (CD11/CD18)-deficient T cells to cultured endothelial cells. J. Immunol., 148, 1093-1101 (1992).
26. Nakamura, T., Takahashi, K., Fukazawa, T., Koyanagi, M., Yokohama, A., Kato, H., Yagita, H. and Okumura, K. Relative contribution of CD2 and LFA-1 to murine T and natural killer cell functions. J. Immunol., 145, 3628-3634 (1990).
27. Kato, K., Tanabe, T., Yagita, H., Agatsuma, T., Hojo, H. and Hashimoto, Y. Adhesion molecules on murine lymphokine-activated killer cells responsible for target cell killing: a role of CD2. Jpn. J. Cancer Res., 82, 1139-1144 (1991).